<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931863</url>
  </required_header>
  <id_info>
    <org_study_id>124/17-04-2019</org_study_id>
    <nct_id>NCT03931863</nct_id>
  </id_info>
  <brief_title>The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section</brief_title>
  <official_title>The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aretaieion University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aretaieion University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the administration of two different doses of
      ondansetron to placebo to prevent hypotension and bradycardia following spinal anaesthesia.
      Apart from haemodynamic parameters (blood pressure and heart rate),characters of the spinal
      blockage (time of onset and regression) will be recorded too.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The day before surgery the procedure will be explained to the patient and the written consent
      will be obtained. In the operating room, intraoperative monitoring will include
      electrocardiography (ECG), noninvasive blood pressure, oxygen saturation by pulse oximetry
      (SpO2) and heart rate (HR). Two peripheral intravenous catheters wil be placed for fluid
      replacement and administration of drugs.

      Participants will be randomly assigned to one of the following groups:

      Group A: Women will receive 4 milligrams (mg) of ondansetron diluted in 100 milliliters (ml)
      of normal saline 0.9 percent 10 minutes before spinal anaesthesia

      Group B:Women will receive 8 mg of ondansetron diluted in 100ml of normal saline 0.9 percent
      10 minutes before spinal anaesthesia

      Group C:Women will receive 100ml of normal saline 0.9 percent 10 minutes before spinal
      anaesthesia

      Subsequently, after receiving 500ml of colloid solution, spinal anesthesia will be performed
      at level L3-L4 or L4-L5 in the vertebral space with 1.6ml of 0.75 percent ropivacaine and
      15mcg of fentanyl, using a 27-gauge pencil point spinal needle with patients in a left
      lateral position. After subarachnoid infusion, participants will be placed supine with left
      uterine displacement and anesthetic and motor blockage will be evaluated every one minute
      until anesthetic blockage reaches the level of T4 neurotome and the motor block becomes
      complete (Bromage grade 3). This time will be called Time to max effect (Tmax).

      Hypotension, defined as systolic blood pressure below 100 millimeters of Mercury (mmHg), will
      be treated using 5mg ephedrine if the heart rate is less than 100 beats per minute or with
      20mcg of phenylephrine if the heart rate is greater than 100 beats per minute. Bradycardia,
      defined as a fall in heart rate below 60 beats per minute will be treated with atropine
      (0.6mg).

      Immediately after the delivery of the neonate, all women will receive a solution of oxytocin
      (20 units) intravenously. Half an hour before the end of the procedure they will receive an
      additional 1g of paracetamol and 75mg of diclofenac.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All solutions will be prepared by an independent researcher who will not be further involved in the study eg data collecting or analyzing them. All solutions will look identical to the anesthetist who will administer them to the patients.Apart from the anesthetist, the surgery staff and the researchers recording the measurements will not know the therapeutic intervention team in which each patient has been randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Systolic Blood Pressure during cesarean section</measure>
    <time_frame>60 minutes</time_frame>
    <description>every one minute after spinal anaesthesia and every five minutes after the delivery of the neonate until the end of the surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Heart Rate</measure>
    <time_frame>60 minutes</time_frame>
    <description>every one minute after spinal anaesthesia and every five minutes after the delivery of the neonate until the end of the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory blockade</measure>
    <time_frame>20 minutes</time_frame>
    <description>Time for onset of sensory block at T4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor blockade</measure>
    <time_frame>20 minutes</time_frame>
    <description>Time to Bromage 2 and to Bromage 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory regression</measure>
    <time_frame>120 minutes</time_frame>
    <description>Time to two segment regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor block regression</measure>
    <time_frame>120 minutes</time_frame>
    <description>Time to Bromage 1 and Bromage 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum effect (Tmax)</measure>
    <time_frame>20 minutes</time_frame>
    <description>Time when the motor blockade is complete and sensory blockade is in at the level of T4 dermatome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to minimum effect (Tmin)</measure>
    <time_frame>120 minutes</time_frame>
    <description>Time to two segment regression of the sensory block (T6) and for motor block regression to Bromage1 and Bromage 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Scale for nausea (0:no nausea 10:worst possible nausea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Number of vomits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shivering</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Yes:shiver No:no shiver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ephedrine consumption</measure>
    <time_frame>60 minutes</time_frame>
    <description>Total ephedrine consumption intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total phenylephrine consumption</measure>
    <time_frame>60 minutes</time_frame>
    <description>Total phenylephrine consumption intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total atropine consumption</measure>
    <time_frame>60 minutes</time_frame>
    <description>Total atropine consumption intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonate Apgar score</measure>
    <time_frame>5 minutes</time_frame>
    <description>Apgar score in the 1st and 5th minute after delivery of the neonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical cord ph</measure>
    <time_frame>15 minutes</time_frame>
    <description>Umbilical cord ph after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for administration of antiemetic agent</measure>
    <time_frame>90 minutes</time_frame>
    <description>Need for administration of antiemetic agent intraoperatively</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4mg</intervention_name>
    <description>Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Onda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 8mg</intervention_name>
    <description>Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Onda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100ml normal saline 0.9 percent</intervention_name>
    <description>Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>N/S 0.9 percent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physical status according to American Society of Anesthesiologists (ASA) I-II

          -  Singleton pregnant women in full term pregnancy

          -  Patients scheduled for cesarean section

          -  Height 158cm-170cm

        Exclusion Criteria:

          -  patient's own refusal

          -  contraindications to spinal anesthesia (coagulation disorders, inflammation at the
             puncture site, allergy to local anesthetics)

          -  ondansetron allergy

          -  body mass index&gt; 33kg / m^2

          -  height &lt;158cm, or&gt; 170cm

          -  hypertensive disorders of pregnancy

          -  cardiovascular disease

          -  receiving selective serotonin reuptake inhibitors (SSRI's) or treatment for migraine

          -  placenta previa.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stavroula Karachanidi</last_name>
    <phone>+306970253686</phone>
    <email>skarahanidi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anteia Paraskeva</last_name>
    <phone>+306972868078</phone>
    <email>aparask@med.uoa.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aretaieio Hospital, University of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anteia Paraskeva, MD</last_name>
      <phone>+306972868078</phone>
      <email>aparask@med.uoa.gr</email>
    </contact>
    <investigator>
      <last_name>Anteia Paraskeva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aretaieion University Hospital</investigator_affiliation>
    <investigator_full_name>Stavroula Karachanidi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ondansetron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

